New From PubMed:

Advancements in the field of biological agents over the course of the last 10 years have led to improved treatments for patients suffering from Crohn’s disease. One effective new option for treating Crohn’s disease is infliximab, a tumor necrosis factor alpha antagonist. However, while infliximab has been shown to induce and maintain remission in both adult and pediatric Crohn’s patients suffering from the luminal and fistulizing types of the disease, the drug is associated with a risk of serious side effects including the potential development of autoanitbodies. Natalizumab has also been found to be an effective treatment in trials, but long-term results of its safety have not yet been obtained. Adalimumab has been proven both safe and effective in trials, and can be administered subcutaneously. For patients with refractory Crohn’s disease, surgery is still a valid treatment option, while autologous stem cell transplantation may be a viable option for patients with a severe form of the disease.

Read the full text of the abstract on PubMed